ST Pharm Co.,Ltd.

KOSDAQ 237690.KQ

ST Pharm Co.,Ltd. Cash and Short-Term Investments for the year ending December 31, 2023: USD 69.19 M

ST Pharm Co.,Ltd. Cash and Short-Term Investments is USD 69.19 M for the year ending December 31, 2023, a 74.47% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

ST Pharm Co.,Ltd. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 39.66 M, a -49.17% change year over year.
ST Pharm Co.,Ltd. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 78.02 M, a -39.57% change year over year.
ST Pharm Co.,Ltd. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 129.10 M, a 130.28% change year over year.
ST Pharm Co.,Ltd. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 56.06 M, a -41.78% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KOSDAQ: 237690.KQ

ST Pharm Co.,Ltd.

CEO	Mr. Geun-Jo Im Ph.D.
IPO Date	June 23, 2016
Location	South Korea
Headquarters	MSA Building
Employees	566
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials Cleaning Supplies Clinical Trials Drugstores & Retail Pharmacies Personal Care Plastics

Description

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.

Key trends

Past 5 years